ROUNDTABLE Ensuring Broad Access to Advanced Therapeutics: The Price is Right?
Wednesday, May 31, 2023 02:15 PM - 03:15 PM
Room 252A
Bioprocessing & Biomanufacturing
Roundtable
Understanding the development cost of advanced therapies, how do we ensure pricing that does not impede access?
Moderators
Julie Allickson, PhD, Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine, Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics, USA
Rosaria Giordano, MD, Medical Director, Fondazione Ospedale Maggiore Policlinico, Italy
Panelists
Anna Sureda, MD, PhD, Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals (Barcelona), Spain
Manu Nair, Chair, Corporate Development, Department of Business Development, Mayo Clinic, USA
Tony Khoury, BSc, Executive Vice President, Project Farma, USA
Learning Objectives
Moderators
Julie Allickson, PhD, Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine, Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics, USA
Rosaria Giordano, MD, Medical Director, Fondazione Ospedale Maggiore Policlinico, Italy
Panelists
Anna Sureda, MD, PhD, Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals (Barcelona), Spain
Manu Nair, Chair, Corporate Development, Department of Business Development, Mayo Clinic, USA
Tony Khoury, BSc, Executive Vice President, Project Farma, USA
Learning Objectives
- Address how ATMPs are delivered to patients today and which modifications of the current pathways are required to improve patients' access, including outside of Europe and North America, in order to promote global equity.
- What are the key challenges and opportunities for biopharma industry with respect to next generation CGT solutions?
- How does CGT infrastructure in Europe vs North America impact these challenges and opportunities?
Julie Allickson
Director, Mayo Clinic Center for Regenerative Biotherapeutics Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine
Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Moderator
Director, Mayo Clinic Center for Regenerative Biotherapeutics Regenerative Biotherapeutics/Associate Professor of Regenerative Medicine
Michael S. and Mary Sue Shannon Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Moderator
Manu Nair LL. M, MBA, LL. B
Chair, Corporate Development, Department of Business Development
Mayo Clinic
Panelist
Chair, Corporate Development, Department of Business Development
Mayo Clinic
Panelist
Anna Sureda MD, PhD
Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme
Institut Català d'Oncologia - Hospital Duran i Reynals (Barcelona)
Panelist
Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme
Institut Català d'Oncologia - Hospital Duran i Reynals (Barcelona)
Panelist